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ABSTRACT
A novel skeletal rearrangement of bicyclo[3.3.1]nonane-2,4,9-trione (16) to an unprecedented highly functionalized bicyclo[3.3.0]octane system
(17), induced by an intramolecular Michael addition, is presented. This novel framework was found to be similarly active to hyperforin (1), against
PC-3 cell lines. A mechanistic study was examined in detail, proposing a number of cascade transformations. Also, reactivity of theΔ7,10-double
bond was examined under several conditions to explain the above results.
Polycyclic polyprenylated acylphloroglucinols (PPAPs)
contain a bicyclo[3.3.1]nonane framework, which is
often found in nature, as a constituent of many bio-
logically active metabolites.1 The chemistry of this
carbon skeleton has been intensively explored for the
construction of complex natural products, as well as
various ring systems.2
Particularly, the great biological properties of hyperfor-
in (1), garsubelin A (2), and other PPAPs (Figure 1) have
intrigued many researchers to focus on the total synthesis
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of these natural products,3 as well as on the preparation
of analogues for SAR studies.4 Our approach to the
bicyclo[3.3.1]nonane system of type A PPAPs is depicted
in Scheme 1. The fully functionalized carbon skeleton of
hyperforin (1) and garsubelin A (2) was constructed in
three steps, employing the readily available deoxycohu-
mulone 5.5
Consequently, our research efforts focused on the re-
moval of the remaining Δ7,10-double bond from the bicyc-
lic system 8, in a regioselective manner. However, the
neopentyl position of this exocyclic double bond proved
to be an unsurpassed obstacle. Many attempts to remove
the Δ7,10-double bond (Table 1) via either hydrogenation
(entries 13) or regioselective isomerization of an allylic
alcohol to the corresponding carbonyl compound (entries
4, 5)6 proved unsuccesful. The difficulty in accessing C-7
was further revealed during the attempted 3,3-sigmatropic
rearrangement of allylic thiocarbonate ester 13 (entry 6).
The molecule refused to furnish a saturated C-7 through
the expected 1,2-sigmatropic rearrangement7 yielding in-
stead ester 14 via an 1,3-sigmatropic rearrangement.
Figure 1. Natural PPAPs.
Scheme 1. Synthetic Approach to Type A PPAPs
Table 1. Selected Examples of Attempts on Δ7,10-Double Bond
Removala
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In parallel, further differentiation of the Δ7,10-double
bond of system 8 was attempted, by converting it to the
more polarized R,β-unsaturated aldehyde 16, after desily-
lation and oxidation of 15 (Scheme 2). All attempted
conditions are summarized in Table 2. Typical Michael
conditions (e.g., PhSH, Et3N, THF) resulted in messy
reaction mixtures (Table 2, entries 68).8
After several attempts, subjection of 16 to PhSH/
piperidine (Scheme 2, eq 1, method A) furnished a single
product, whose 1H NMR spectrum supported the desired
deacetylated structure 18, except for a significant shift
observed for Ha (δ 2.04f2.78). To our surprise, X-ray
analysis revealed the structure of the deacetylated 5,5-
bicyclic framework 17 (Figure 2), which is locked in an
intramolecular hydrogen bonded ring (O 3 3 3O 2.523 A˚),
explaining Ha deshielding (see Supporting Information
(SI) for complete experimental details).
Further experimentation on Michael coupling condi-
tions was needed in order to clarify the mechanism of the
new reaction. Application of the same conditions on the
pivaloate derivative 20 (Scheme 2, eq 2) resulted only in
Δ7,10-double bond isomerization product 21, proving that
protective group removal was necessary for the rearrange-
ment to proceed. Additionally, deprotection of 16 using
MeONa/MeOH resulted in the formation of unstable
alcohol 19 which was subsequently converted to 17 using
PhSH/piperidine.
Several other bases were also used (Table 2), clarifying
that this skeletal rearrangement is not related to pH, but it
proceeds only in the presence of a primary or a secondary
amine (entries 1013 vs entries 69).
The latter findings suggest the formation of a possible
imine intermediate. Accordingly, we propose the following
mechanism (Scheme 3). The exposed allylic aldehyde 19
should be the most accessible carbonyl against amines.
Imine formation of the above moiety augments the elec-
trophilicity at C-7, enabling thus an attack of the C-3
enolate anion, derived from the resonated unprotectedC-4
hydroxyl group (22f23). Had this highly strained tricyclic
system 23 been formed, it may release strain via eight
possible retro-aldol reactions (two from C4-carbonyl,
three from C2-carbonyl, and three from C9-carbonyl).
Cleavage of C1C9 or C1C2 bonds (pathway 1 or 2)
should be more favorable, since they both could lead to a
delocalized enolate system. Noticeably, out of all the
possible derivatives, 23 affords the 5,5-ring system 24
versus the 6,5-ring system 25, in a high yield.
Table 2.Michael Addition Attempts on Aldehyde 16
entry base/Nu/solvent t
product
(% yield)
1 /PhSH/THF 25 to 60 C no reaction
2 /PhSH/CH2Cl2 25 to 40 C no reaction
3 /PhSH/ 25 to 60 C no reaction
4 pyridine/PhSH/THF 25 to 60 C no reaction
5 PPTS/PhSH/THF 0 to 60 C no reaction
6 DMAP/PhSH/THF 25 C messy reactiona
7 Et3N/PhSH/THF 0 to 25 C messy reactiona
8 Et3N/PhSH/CH2Cl2 0 to 25 C messy reactiona
9 a. MeONa/MeOH 25 C no reaction
b. DBU/PhSH/THF
10 piperidine/PhSH/THF 25 C 17 (73%)
11 a. MeONa/MeOH 25 C
b. piperidine/PhSH/THF 17 (81%)
12 a. MeONa/MeOH 25 C
b. Bu2NH/PhSH/THF 17 (70%)
13 a. MeONa/MeOH 25 C
b. BuNH2/PhSH/THF 17 (79%)
14 MeONa/MeOH 25 C 19
aDeacetylation product 19 was initially formed.
Figure 2.Molecular structure of 17 (left) and detailed view of the
bicyclic corewith the intramolecularH-bond (right).O (red) and
S (yellow) atoms are presented as exaggerated spheres.
Scheme 2. Michael Approach to PPAPs
(8) Other attempts for hydride addition on R,β-unsaturated alcohol
11 (e.g., [(PPh3)CuH]6 or NaBH4/AcOH) also failed.
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Preliminary screening of this novel framework was
performed. Hyperforin (1) and its derivatives have been
reported to show target specific antitumor activity through
the Akt1-mediated antiproliferative and apoptotic path-
way.9 Thus, 1 and 17 were assessed for antiproliferative
activity in the androgen-unresponsive, grade IV, PC-3
cell line. PC-3 cells are highly metastatic with constitu-
tive expression of the EGFR oncogene and downstream
activation of the Akt1 pathway. Surprisingly, compound
17 showed similar antiproliferative efficacywith 1 (Table 3),
while both were more potent than reference compound
R-TOS9 (SI).
In conclusion, the reactivity of the Δ7,10-double bond of
bicyclic acyl phloroglucinol systems 8 and 16 were exam-
ined, under various conditions. Due to severe steric hin-
drance, the only successful tranformation was that to the
bicyclic[3.3.0]octane systemviaan intramolecular rearrange-
ment. The above findings open a new route to a novel
class of bioactive acylphloroglucinol analogues. Current
efforts focus on extending the utility of this novel trans-
formation, as well as further dissecting the molecular
mechanism of its bioactivity.
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Table 3. Antiproliferative Efficacy (IC in μg/mL)
compound IC20 IC50 IC80
R-TOSa 17.25 43.13 69.01
1 7.54 18.85 30.17
17 9.62 24.05 38.48
aR-TOS = R-tocopherol succinate.
Scheme 3. Proposed Mechanism of Michael-Induced Skeleton
Rearrangement
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